A recent decision at the European Patent Office will be incredibly important to the pharmaceutical and biotech industry since it may potentially be used to evaluate the technical support of thousands of patent applications (and issued patents) that have already been filed.
Per Larsen explains the decision and the potential impact in this article.
This site is owned by aera a/s, and is for commercial and informational purposes only. The content is not intended as legal advice, and it should not be used as such.
aera a/s will at all times do its utmost to keep this site fully updated. However, aera a/s disclaims any direct or indirect damage resulting from entering this site, or using the information contained in the site.
Material from this site can only be reproduced, distributed, or otherwise made public with prior permission from aera a/s.